What Two MedTech Events Taught Me About Where the Industry Is Heading
Authored by Becky Dahler
Two weeks. Two cities. Two very different conversations about where MedTech is heading in 2026.
I was in Detroit for the Project MedTech Midwest Showcase, then in West Palm Beach for MedTech World North America. Here is what I keep coming back to.
The loudest signal I heard, repeated across panels and hallway conversations at MedTech World: clinical outcomes are no longer a differentiator. They are the floor. If your device works, congratulations — so does everyone else’s in the room. The real question investors are asking now is what comes after the clinical data.
Specifically, they want answers to three things:
- Can the hospital actually get reimbursed for it?
- Does it fit into existing clinical workflows, or does it require behavior change?
- Does it generate savings on a timeline that payers care about?
If you cannot answer all three cleanly, the clinical story does not matter as much as you think it does.
On exits: the $40M revenue benchmark kept surfacing as a meaningful threshold — not a guarantee, but a signal that a company has de-risked enough to be acquisition-ready. That number is worth knowing if you are building toward a strategic exit.
Regulatory was another consistent theme. Investors are treating FDA pathway clarity — whether that is 510(k), De Novo, or PMA — as a filter before they go deep on due diligence, not something to figure out post-fundraise. Founders who walk in already knowing their pathway and their predicate strategy are starting from a completely different position.
On the corporate venture side: Medtronic Ventures, JJDC, and others are moving earlier and more deliberately than they were even two years ago. If you are not thinking about strategic capital alongside traditional VC, you should be.
The topic areas generating the most energy across both events: AI-enabled devices, women’s health, longevity, and at-home diagnostics. Not surprising, but the level of serious investor attention behind those categories was notable.
And the Detroit conversation specifically — the Midwest MedTech ecosystem is genuinely underrecognized. World-class health systems, a strong and collaborative startup community, and real commercial infrastructure. It is punching above its weight, and I think that changes in the next few years.
If you are a founder trying to navigate any of this — fundraising, regulatory strategy, health system partnerships — I would love to connect and hear what you are working on.
What is the biggest gap you are seeing between what investors say they want and what they actually fund?
About the Author
Becky Dahler is passionate about driving growth and operational excellence in MedTech, with a proven track record of leading multi-million-dollar initiatives that accelerate innovation and improve patient outcomes.
Becky has over 25 years of relevant industry experience which has included working with four MedTech start-ups — two successful and two that provided invaluable lessons—as well as work with Fortune 100 MedTech organizations. This breadth of perspective enables Becky to bring practical, end-to-end expertise to a MedTech product and help guide it efficiently and strategically to market.